February 22nd 2024
Research and development funding increased in 2023 but clinical trial starts fell by 15%, partly because of fewer COVID-19-related trials, according to IQVIA's worldwide report on research and development in the biopharmaceutical industry.
Merck tells physicians to stop prescribing Tredaptive
January 15th 2013Merck is halting sales of its cholesterol drug-extended-release niacin/laropiprant (Tredaptive)-after preliminary data from a study showed that it did not achieve its primary end point of reduction of major vascular events and also raised safety concerns.
Read More
Canagliflozin may not be good for the heart, FDA says
January 10th 2013Canagliflozin (Janssen Research & Development), developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, raised the level of bad cholesterol in patients during clinical trials and may post heart risks, according to FDA and reported by Reuters.
Read More
Antimicrobial stewardship programs-A review for the formulary decision-maker
December 31st 2012Antimicrobial stewardship programs are being implemented in a variety of settings to assist with the challenges associated with the management of infectious diseases. Here's a review of ASPs from the perspective of a formulary decision-maker.
Read More
Bariatric surgery can help, but not cure, diabetes
December 31st 2012Gastric bypass surgery can improve glycemic control in adults with type 2 diabetes, but doesn't cure diabetes, according to the largest community-based study of long-term diabetes outcomes after bariatric surgery, published online ahead of print in Obesity Surgery.
Read More
Recent FDA action (through December 2012) related to, Rabeprazole sodium delayed-release sprinkle capsules, CXA-201, CB-215, Buprenorphine subdermal implant, LX1033, ISIS-TTR Rx, Digoxin Immune Fab, Glucagon, AAV1-FS344, Trans sodium crocetinate, Betamethasone valerate foam 0.12%
Read More
African-Americans more likely to die at first coronary event
December 31st 2012African-American men and women continue to have higher risks of dying at the first presentation of heart disease compared with their white counterparts, according to a study published in the Journal of the American Medical Association.
Read More
FDA Actions in Brief December 2012
December 31st 2012Recent FDA Approvals (through December 2012) related to (Bedaquiline, Janssen, Oseltamivir, Genetech, Apixaban, Bristol-Myers Squibb, Lomitapide, Aegerion, Varicella zoster immune globulin preparation, Cangene, Teduglutide, NPS Pharmaceuticals, Pasireotide diaspartate, Novartis, Ponatinib, ARIAD Pharmaceuticals, Influenza virus vaccine, GlaxoSmithKline, Raxibacumab, Crofelemer, Salix, Cabozantinib, Exelixis)
Read More
Individuals with high cholesterol who stay on their statin medications over a 2-year period are healthier than comparable nonadherent individuals, but the overall cost of their care is slightly higher, according to a new study presented at the Academy of Managed Care Pharmacy 2012 Education Conference, in Cincinnati, Ohio, in October.
Read More
Escitalopram reduces the risk of depression in patients with HCV treated with interferon alpha
December 1st 2012Pre-emptive therapy with the selective serotonin reuptake inhibitor escitalopram in patients initiating interferon therapy for hepatitis C virus (HCV) without psychiatric risk factors reduced the risk of depression, according to a recent study published in the Annals of Internal Medicine.
Read More
Invermectin lotion eliminates head lice with 1 application
December 1st 2012Topical ivermectin provided a good degree of cure in patients with head lice infection with 1 simple and easy-to-use application, according to a study published in the November 1 issue of the New England Journal of Medicine.
Read More